Hypertension Not a Predictor for Pazopanib Efficacy

Share this content:
Pazopanib-induced hypertension did not correlate with outcome in pazopanib-treated soft tissue sarcoma patients.
Pazopanib-induced hypertension did not correlate with outcome in pazopanib-treated soft tissue sarcoma patients.

In a retrospective analysis, pazopanib-induced hypertension (HTN) did not correlate with outcome in pazopanib-treated soft tissue sarcoma (STS) patients, meaning the occurrence of HTN cannot serve as a biomarker in this setting, according to an article published online ahead of print in the European Journal of Cancer.1

The rationale for the study was that HTN is an on-target effect of vascular endothelial growth factor (VEGF)-receptor inhibitors, such as pazopanib. Reliable biomarkers for the efficacy of pazopanib in soft-tissue are lacking.

Researchers sought to evaluate associations between pazopanib-induced hypertension and antitumor efficacy in patients with metastatic non-adipocytic STS.

Associations were retrospectively assessed across 2 prospective studies: European Organisation for Research and Treatment of Cancer (EORTC) study 62043 and 62072, in metastatic patients who received pazopanib 800 mg daily. Enrollment was restricted to patients with a baseline blood pressure (BP) < 150/90 mmHg. BP was measured monthly.

The effect of HTN developing in patients without baseline anti-HTN medications was assessed on progression-free survival (PFS) and overall survival (OS) using a landmark analysis stratified by study; univariately using the Kaplan-Meier method and a log-rank test, and in a multivariate Cox regression model after adjustment for important prognostic factors.

RELATED: Surgery May Provide Most Benefit for Interdigitating Dendritic Cell Sarcoma

Findings showed that of 337 patients, 21.7% received anti-HTN medications at baseline and had a similar PFS and OS compared to those who did not. In patients without baseline anti-HTN medications, 38.6% developed HTN, mostly within the first 5 weeks of receiving pazopanib.

There was no effect on PFS or OS from occurrence of HTN within 5 weeks of treatment expressed either in NCI-CTCAE criteria or as maximal differences from baseline in systolic and diastolic BP.

Reference

  1. Duffaud F, Sleijfer S, Litiere S, et al; Hyptertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials. [published online ahead of print August 25, 2015]. EJC. doi: 10.1016/j.ejca.2015.08.002.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters